M. Prieto - Concepedia

Author

M. Prieto

Hospital Universitari i Politècnic La Fe ORCID

Also Known As

A. Martínez-Ortí, Ana Moreno-Zamora, M PRIETO, M Prieto, M. A. Prieto, M. I. Prieto, M. Prieto, M.-C. Prieto, Manuel Sanchez Prieto, Maria A. Prieto

351

Publications

13.6K

Citations

H-Index

193

Concepts

All Affiliations

Hospital Universitari i Politècnic La Fe Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Universitat de València Hospital Clínic de Barcelona Hospital Universitario Puerta de Hierro Majadahonda

About

M. Prieto is an author at Hospital Universitari i Politècnic La Fe specializing in medicine, hepatology, and liver transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	68	7.3K
2	Health Sciences	9	9	1.1K
3	Engineering	6	6	390
4	Natural Sciences	3	3	188
5	Public Health	3	3	135

M. Prieto

128

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
HCV-related fibrosis progression following liver transplantation: increase in recent years Marina Berenguer, Linda D. Ferrell, Jessica J. Watson, Journal of Hepatology HepatologyViral HepatitisHepatitisPathologyComplications Of Cirrhosis	2000	746
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Marina Berenguer, M. Prieto, Fernando San Juan, Hepatology Solid Organ TransplantationPathologyCirrhosisAutoimmune Liver DiseasePosttransplantation Hcv-fibrosis Progression	2002	599
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Marina Berenguer, M. Prieto, José Miguel Rayón, Hepatology	2000	539
High Incidence of Allograft Cirrhosis in Hepatitis C Virus Genotype 1B Infection Following Transplantation: Relationship With Rejection Episodes M. Prieto, Marina Berenguer, José Miguel Rayón, Hepatology	1999	536
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial Michael P. Manns, Didier Samuel, Edward Gane, The Lancet Infectious Diseases HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	2016	442
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Yun‐Fan Liaw, I‐Shyan Sheen, Chuan–Mo Lee, Hepatology	2010	319
Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury Mercedes Robles‐Díaz, M. Isabel Lucena, Neil Kaplowitz, Gastroenterology HepatologyLiver PhysiologyHepatitisSepsisHepatotoxicity	2014	319
Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes Véronique Menet, M. Prieto, Alain Privat, Proceedings of the National Academy of Sciences Vimentin GenesNeuroregenerationSpinal Cord InjuryReactive AstrocytesAxonal Plasticity	2003	308
Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation Marina Berenguer, Antoni Palau, Victoria Aguilera, American Journal of Transplantation TransplantationHepatologyHepatitis CViral HepatitisAntiviral Therapy	2008	280

Page 1